Other Amplified Genes with Clinical Potential

a-Methylacyl-coenzyme A (CoA) racemase (AMACR) is an enzyme involved in the b oxidation of dietary branched-chain fatty acids. It is overexpressed in prostate cancer at both the RNA and protein level [9]. Recent work has identified AMACR as a new diagnostic marker for prostate cancer needle biopsies [9]. It is also an androgen-independent growth modifier and so has the potential to be a complementary target with androgen ablation in prostate cancer treatment [31].

Another gene product that is overexpressed in prostate cancer is fatty acid synthetase (FAS). Inhibitors to FAS are therefore also being investigated as a therapeutic target in the disease [9].

0 0

Post a comment